| Literature DB >> 24243013 |
Dan H Barouch1, Kathryn E Stephenson, Erica N Borducchi, Kaitlin Smith, Kelly Stanley, Anna G McNally, Jinyan Liu, Peter Abbink, Lori F Maxfield, Michael S Seaman, Anne-Sophie Dugast, Galit Alter, Melissa Ferguson, Wenjun Li, Patricia L Earl, Bernard Moss, Elena E Giorgi, James J Szinger, Leigh Anne Eller, Erik A Billings, Mangala Rao, Sodsai Tovanabutra, Eric Sanders-Buell, Mo Weijtens, Maria G Pau, Hanneke Schuitemaker, Merlin L Robb, Jerome H Kim, Bette T Korber, Nelson L Michael.
Abstract
The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine development. HIV-1 mosaic antigens are bioinformatically optimized immunogens designed for improved coverage of HIV-1 diversity. However, the protective efficacy of such global HIV-1 vaccine antigens has not previously been evaluated. Here, we demonstrate the capacity of bivalent HIV-1 mosaic antigens to protect rhesus monkeys against acquisition of infection following heterologous challenges with the difficult-to-neutralize simian-human immunodeficiency virus SHIV-SF162P3. Adenovirus/poxvirus and adenovirus/adenovirus vector-based vaccines expressing HIV-1 mosaic Env, Gag, and Pol afforded a significant reduction in the per-exposure acquisition risk following repetitive, intrarectal SHIV-SF162P3 challenges. Protection against acquisition of infection correlated with vaccine-elicited binding, neutralizing, and functional nonneutralizing antibodies, suggesting that the coordinated activity of multiple antibody functions may contribute to protection against difficult-to-neutralize viruses. These data demonstrate the protective efficacy of HIV-1 mosaic antigens and suggest a potential strategy for the development of a global HIV-1 vaccine. PAPERCLIP:Entities:
Mesh：
Substances：
Year: 2013 PMID： 24243013 PMCID： PMC3846288 DOI： 10.1016/j.cell.2013.09.061
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582